申请人:Yoshida Ichiro
公开号:US08476301B2
公开(公告)日:2013-07-02
A compound represented by formula (1) or a pharmaceutically acceptable salt thereof has an inhibitory effect in the fractalkine-CX3CR1 pathway:
wherein R represents a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, a C3-8 cycloalkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, or a C3-8 cycloalkenyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, X represents a C1-6 alkyl group, Y and Z are the same or different from each other and each represents a halogen atom or a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group B, n represents 0 or 1, Substituent Group A consists of halogen atoms, and Substituent Group B consists of halogen atoms.
化合物的化学式表示为(1),或其药学上可接受的盐,对fractalkine-CX3CR1途径具有抑制作用:其中R代表未取代或取代有1至3个从取代基团A中选择的基团的C1-6烷基基团,未取代或取代有1至3个从取代基团A中选择的基团的C3-8环烷基基团,或未取代或取代有1至3个从取代基团A中选择的基团的C3-8环烯基基团,X代表C1-6烷基基团,Y和Z相同或不同,每个代表卤素原子或未取代或取代有1至3个从取代基团B中选择的C1-6烷基基团,n代表0或1,取代基团A由卤素原子组成,取代基团B由卤素原子组成。